By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Lytix Biopharma 

P.O. Box 6447
Tromso Research Park
Tromso    N-9294  Norway
Phone: Fax:


SEARCH JOBS


Industry
Pharmaceutical

Segment
Start Up





Company News
Lytix Biopharma and KAEL–GemVax Announce First Patient Treated in Clinical Trial to Combine LTX-315 and GV1001 Cancer Vaccine Immunotherapy 12/6/2010 11:50:35 AM
Lytix Biopharma Announces Approval by Hungarian Authorities and Ethics Committee to Start Phase IIa Clinical Trial with LytixarTM (LTX-109) in Gram Positive Skin Infections 9/1/2010 8:21:28 AM
Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy 6/8/2010 10:54:48 AM
Lytix Biopharma Announces Regulatory Approval by Swedish Authorities to Commence Phase I/IIa Clinical Trial with LytixarTM (LTX-109) in MRSA 5/24/2010 10:47:24 AM
Lytix Biopharma as Update on Phase I Progress with Oncopore(TM) for Solid Tumors 5/20/2010 10:53:58 AM
Lytix Biopharma Announces Regulatory Approval by Norwegian and Swedish Authorities to Commence Phase I Clinical Trial of Oncopore(TM) (LTX-315) in Cancer 12/15/2009 9:07:16 AM
Lytix Biopharma Closes $10.4 Million Funding Round 1/22/2009 6:18:43 AM
Lytix Biopharma Presents LTX-109 Anti-Microbial Data at ICAAC Novel Antimicrobial Drug Demonstrates Ultra-Rapid Effectiveness Against Broad Range of Drug-Resistant Pathogens 11/20/2008 10:57:36 AM
Lytix Biopharma Reveals Further Details on First Cancer Candidate Oncopore at BIO 2008 6/17/2008 10:58:00 AM
Lytix Biopharma to Take Lead Cancer Compound into Clinic 3/31/2008 11:46:53 AM
12
//-->